	Reference	Specie	Exposure period	Route	Doses	Age at analyses	Neuroanatomical and hormonal analyses
	Sexually dimorphic populations						
DEVELOPMENTAL	59	Sprague-Dawley rat	GD15-PND10	Diet	BPA: 60 - 600 - 3000 ppm NP: 60 - 600 - 3000 ppm	Adult (Intact)	No modification of the SDN-POA volume.
	56	Sprague-Dawley rat	PND1-PND2	Subcutaneous (4 injections)	BPA: 250 µg/50 µL Genistein: 250 µg/50 µL 17β-E2:	Juvenile (PND19)	E2, but not BPA or genistein, reduced the number of TH-ir in the AVPV. No effects on ERα-ir neurons. Reduction of the number of TH-ir neurons co-expressing ERα. BPA and genistein reduced the number of TH-ir neurons co-expressing ERα.
	53	Sprague-Dawley rat	GD6-PND21	Oral (gavage)	BPA: 2.5- 25 µg/kg EE: 5 - 10 µg/kg	Juvenile (PND21)	EE, but not BPA, increased the SDN-POA volume.
	54	Long-Evans rat	GD12-PND10	Oral (dosed-cookie)	BPA: 10 - 100 - 1000 - 10000 mg/kg E2: 2 µg/kg/d (n = 2 data not shown)	Adult	Decreased TH-ir cell numbers in the female AVPV across all exposure groups. SDN-POA volume was unaltered in females but decrease in males BPA-treated at all doses. Decreased of calbindin-ir cell number in all but the BPA 1000 treated-group.
	58	Sprague-Dawley rat	GD15-PND10	Diet	MXC: 24 - 240 - 1200 ppm Genistein: 20 - 200 -1000 ppm DINP: 400 - 4000 - 20000 ppm	Adult (11 weeks of age)	Unchanged SDN-POA volume at all treatments.
	Sex steroid receptors and neuropeptides						
	114	Wistar rat	PND1-PND7	Subcutaneous	BPA: 0.05 - 20 mg/kg DES: 0.02 mg/kg	PND8 and PND21	Opposite effecst of BPA treatment dependending on administered dose. Treatment with 20 mg/kg BPA reduced mRNA expression and protein level of ERα in the preoptic area, whereas exposure to 0.05 mg/kg increased ERα expression compared to controls. DES decreased ERα mRNA expression in the preoptic area at PND8, and ERα protein levels at PND8 and PND21.
	110	Sprague-Dawley rat	PND23-PND30	Oral (micropipette)	BPA: 40 µg/kg EE: 0.4 µg/kg	PND37 and adult in estrus	BPA and EE increased number of ERα-ir neuron in the arcuate nucleus at PND37 and in the preoptic area at both ages. EE increased estradiol levels at PND90.
	111	Wistar rat	PND1-PND7	Subcutaneous	BPA: 0.05 - 20 mg/kg	Adult (OVX + E2)	Increased ERα expression in the AVPV and decreased ERα expression in the arcuate nucleus in BPA-treated females with both doses. Reduction of PR expression in the AVPV of BPA-treated females with 0.05 mg/kg. Reduced LH levels at BPA-20.
	113	Long-Evans rat	PND0-PND2	Subcutaneous	BPA: 50 µg/kg- 50 mg/kg EB: 10 µg	PND4 and PND10	BPA 50 µg/kg: decreased ERα mRNA expression (in situ hybridization) in the AVPV at PND10; no effect at PND4. BPA 50 mg/kg: Increased ERα mRNA expression in the AVPV and MPOA at PND4; decreased ERα mRNA expression at PND10. No modification of ERα expression in the VMH and ARC. Decreased ERβ mRNA expression in the AVPV and MPOA at PND10 at both doses, and Kiss1 mRNA expression in the RP3V nucleus at PND10. BPA-induced changes are different from those induced by EB.
	102	Sprague-Dawley rat	GD6-GD21	Oral (gavage)	BPA: 2.5 - 25 µg/kg/d EE: 5 - 10 µg/kg/d	PND1	No effect of BPA or EE treatment on Esr1 or Esr2 expression in the AVPV and MPOA. Significative effects since BPA-2.5 in the MBH and amygdala.
	105	BALB/c mouse	GD0-GD19	Oral	BPA: 2 - 20 - 200 µg/kg	PND28	Low-dose prenatal BPA exposure induced lasting epigenetic disruption in the brain which are sex-specific, dose-dependent and brain region-specific. BPA altered mRNA levels of epigenetic regulators (DNMT) 1 and DNMT3A in the juvenile cortex and hypothalamus, paralleling changes in estrogen-related receptors. Changes in ERα and DNMT expression in the hypothalamus were associated with DNA methylation changes in the ERα gene.
	103	Long-Evans rat	PND0-PND2	Subcutaneous	BPA: 50 µg/kg/d - 50 mg/kg/d EB: 10 µg/kg/d	PND4 and PND10	BPA: Decreased Esr2 mRNA expression in the BNST of 50 mg/kg treated-females at PND10. Increase Esr2 mRNA in the PVN of 50 µg/kg treated-females at PND10. In the MeA, BPA at both doses decreased Esr2 expression on PND 4. EB: Decreased Esr2 mRNA expression in the BNST at PND10, PVN at PND4 and 10 and in the MeA at PND4.
	115	Sprague-Dawley rat	GD6-GD21 then PND1-PND21 or PND90	Oral (gavage)	BPA: 2.5 - 25 - 260 - 2700 µg/kg.j EE: 0.5 - 5 µg/kg/d	PND21 and PND90	PND21: Expression of Esr1altered by BPA-25 and EE-5 in the AVPV/MPOA, masculinized by EE-5 in the MBH. PND90: Expression of Esr1masculinized by EE-0.5 and 5 in the AVPV/MPOA. Expression of Esr2 reduced by BPA and EE at all doses in the AVPV, by EE-0.5 and 5 and BPA-2.5 in the MPOA.
	108	C57BL6J mice	PND23-PND31	Subcutaneous	BPA: 50 µg/kgd EB: 10 µg/kg/d	PND90	ERα immunoreactivity increased by BPA in the BST, ARC, VMH and MeA and by EB in the LS and BST. No effect of both compounds in the MPOA, VMH and MeA.
	109	Sprague-Dawley rat	GD6-birth	Oral (gavage)	BPA: 0 - 2.5 -25 - 250 - 2500 - 25000 µg/kg/d EE: 0.05 - 0.5 µg/kg/d	PND1	RNA sequencing: Gene expression changes mainly observed in the hypothalamus. qRT-PCR: BPA increased hypothalamic expression of *Esr1*, *Esr2* and *oxytocin*. EE did not fully mimic the masculinization effects of estradiol.
	107	C57BL/6J mouse	GD0-birth	Diet	BPA: 5 mg to each kg of diet (BPA produced in serum equivalent to humans)	Adult	Decreased ERα-ir cell number in the VMH of F1 BPA-treated females. Decreased ERα-ir cell number in the BNST of the third generation of BPA-treated females. No effect on E2 levels on F3 females.
	116	Fisher CDF rat	Exp1: GD18-GD21, PND0-PND7 Exp2: GD11-GD21, PND0-PND7	Injection	Exp1: BPA: 50 µg/kg/d - 50 mg/kg/d Exp2: BPA 50 mg/kg DEHP: 500 mg/kg/d MXC: 75 mg/kg/d DES: 0.1 µg/kg/d	PND50-60 (Exp1) PND70-90 (Exp2)	Exp1: BPA altered the expression of Chrm3, Adipor1 in a dose dependent manner as well as Bdnf, Cck2r, Htr2c, and Igf1expression in the arcuate nucleus. Exp2: BPA and MXC suppressed the expression of Htr2c. DEHP and MXC suppressed the expression of Adipor1. DES treatment altered Bdnf expression and both DES and BPA increased the expression of Igf1. MXC altered Chrm3 expression.
	104	CD(SD)IGS rat	GD15-PND10	Diet	Genistein: 1000 ppm MXC: 24 - 240 - 1200 ppm DINP: 4000 - 20000 ppm EE: 0.05 ppm	PND10	EE increased expression of ERβ and PR in the POA; no changes in the expression of ERα, SRC1, SRC2, calbindin or GnRH. MXC increased PR expression at 1200 ppm and reduced ERβ mRNAs levels at 240 ppm. DINP at 20000 ppm decreased PR expression. Gen did not trigger changes in the gene expression levels.
	112	Fisher CDF rat	GD19-GD22 then PND0-PND7	Injection	MXC: 20 mg - 100 mg/kg/d EB: 1 mg/kg/d	Adult (16-17 months of age)	15 POA genes were up-regulated in EB and high-dose MXC groups. Gene expression of *Kiss1* and *Esr1* was affected by both treatments in the POA. High percentage of methylation at CpG sites in Esr1 promoter of EB-treated females. Serum levels of estradiol, but not progesterone, were lowered by MXC and EB treatments.
ADULT	117	ICR mice	Adult 12 week-old females 6 h at	Oral or ICV	Oral BPA: 20 µg/kg/d ICV BPA: 0.02, 0.2, 2, 20 and 200		Increased GnRH and kisspeptin expression in the POA. Effects reproduced by ICV injection of BPA. BPA potentiates E2-induced kisspeptin expression in the AVPV.
	118	Sprague-Dawley rat	1 week	Subcutaneous	Diet: coumestrol (0.01%)	OVX females ± 17β-E2	17β-E2 reduced ERβ, while coumestrol increased mRNAs levels in the PVN. No effects in the BNST or MPOA.